Skip to content
Open access

Antibody 3CF5 neutralizes historical and emerging H5Nx influenza viruses by targeting a conserved non-receptor-binding hemagglutinin epitope.

Oct 2026 · Cell Reports · Vol 45 11, pp. 118180 · 0 citations · 74 references
Medicine

TL;DR

Cryo-electron microscopy analysis revealed that 3CF5 targets a conserved non-receptor-binding epitope on the hemagglutinin (HA) head, spanning the vestigial esterase domain and an adjacent lateral surface, which mediates neutralization primarily through inhibiting membrane fusion and also possesses antibody-dependent cellular cytotoxicity.

Abstract

Avian influenza viruses of the H5Nx subtype pose persistent pandemic threats. Here, we immunized rhesus macaques with an H5N6 vaccine and obtained 30 H5-reactive monoclonal antibodies (mAbs). Three IgG mAbs, 3CF5, 3BG3, and 3BE7, demonstrated potent neutralizing activity against multiple H5Nx viruses and conferred protection in a lethal mouse challenge model. Notably, 3CF5 exhibited broad neutralization against H5Nx viruses spanning 1997-2024, including contemporary clade 2.3.4.4b H5N1 strains associated with an ongoing outbreak in dairy cattle. Cryo-electron microscopy (cryo-EM) analysis revealed that 3CF5 targets a conserved non-receptor-binding epitope on the hemagglutinin (HA) head, spanning the vestigial esterase domain and an adjacent lateral surface. 3CF5 mediates neutralization primarily through inhibiting membrane fusion and also possesses antibody-dependent cellular cytotoxicity. Furthermore, isotype conversion of 3CF5-IgG to mucosal secretory IgA1 (sIgA1) enhanced neutralization potency against H5N1 viruses up to 128-fold, highlighting the advantage of sIgA1 as a nasally administered prophylactic agent.

Read PDF

Similar papers

Open access Oct 2026

Antibodies targeting a conserved cryptic epitope at the influenza hemagglutinin head-stem interface via distinct binding modes

Influenza A virus continues to pose pandemic threats, as demonstrated by the recent global spread of highly pathogenic H5N1 strains. Consequently, the development and characterization of vaccines targeting zoonotic influenza subtypes have become a major focus of the field. In this study, we characterize two broadly rea...

Guthrie L. Stroh, Hui-Bin Lv, Chun-Ke Chen et al. · 0 citations
Open access Oct 2026

An adenovirus-based mucosal vaccine induces cross-neutralizing antibodies and protects against lethal H5N1 infection in ferrets

Second-generation VXA-H5–02 is a promising vaccine candidate capable of inducing systemic and mucosal immunity, offering broad protection against HPAI, and significantly reduced illness, viral burden, and shedding.

Becca A. Flitter, Ka-Yan Tam, Laura J. Showalter et al. · 0 citations
#protein folding Open access Oct 2026

A multi-epitope-based DNA vaccine confers cross-protection against influenza A H1N1 and H3N2 viruses

This multi-epitope DNA vaccine elicited cross-protective immunity against influenza A/H1N1 and A/H3N2 by targeting conserved HA and PA epitopes, supporting its potential as a candidate for universal influenza vaccine development.

K. Barkhordari, F. Rezaei, V. Salimi et al. · 0 citations
Open access Oct 2026

A digitally immune-optimized influenza vaccine broadly neutralizes swine and human H1N1 influenza viruses and protects from heterologous challenge

ABSTRACT Influenza A virus (IAV) zoonotic transmission and continuous evolution in multiple host species heighten the risk of emerging novel strains at the human-animal interface. Digitally immune-optimized hemagglutinin (HA), neuraminidase (NA), and matrix-2 (M2) vaccine antigens were engineered and combined as a sing...

J. D. Del Rosario, P. V. van Diemen, Simon D. W. Frost et al. · 0 citations
Oct 2026

Antibodies to distinct epitopes on MPXV enveloped virion provide additive and complete protection.

The continuing evolution of monkeypox virus (MPXV) clades capable of sustained human-to-human transmission poses an escalating global health risk, yet no effective therapy exists for poxvirus infection. Here, we investigate a panel of human monoclonal antibodies (mAbs), derived from an antibody library, which targets A...

Ding Zhang, R. Fantin, Xue-Yong Zhu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.